Fms-like tyrosine kinase 3 (FLT3) is mutated in approximately 90% of AML patients, and FLT3-ITD is a common mutation in FLT3, accounting for approximately 20% of AML patients, and is more malignant. This evidence concerns the gene FLT3 and acute myeloid leukemia.